Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Prothena Corporation plcNASDAQ: PRTA

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue falls 79.4% from a year ago

Deferred revenue stood at $1.63M at the end of Q1 FY2026, down 79.4% from a year earlier and down 38.8% from the prior quarter. Over 3 fiscal years it compounded at -38.5% a year.

Context

  • Deferred revenue amounted to 0.5% of total assets at the end of Q1 FY2026, down 1.1 pp from a year earlier.
  • Deferred revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -79.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.63M-38.8% QoQ
Last fiscal yearDec 2025
$2.66M-69.9% YoY
Year agoMar 2025
$7.9M-79.4% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-79.4%——
1 year-69.9%——
3-year CAGR-38.5%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
2.66M USD
Year-over-year change
-69.9%
4-year CAGR
-23.2%

Deferred Revenue vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -79.4% is the 3rd highest of 4, against a peer median of -2.9%.
  • Deferred revenue amounts to 0.5% of total assets for PRTA, versus a peer median of 0.0%.
PRTA Competitors
Deferred Revenue for PRTA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ACIUAC Immune S.A.Mar 2026CHF 83.64M CHF-1.2%—60.9%
PRTAProthena Corporation plcMar 2026$1.63M USD-79.4%-38.5%0.5%
AVXLAnavex Life Sciences Corp.Dec 2025$805K USD-2.9%+22.0%0.6%
CGTXCognition Therapeutics, Inc.Mar 2026$220K USD-79.4%-40.0%0.6%
BIIBBiogen Inc.Jun 2026$0 USD——0.0%
DNLIDenali Therapeutics Inc.Jun 2026$0 USD——0.0%
ANNXAnnexon, Inc.Mar 2026$0 USD——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 USD——0.0%
PMNProMIS Neurosciences, Inc.Jun 2026$0 USD——0.0%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding PRTA) —-2.9%-9.0%0.0%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents579.09M710.41M618.83M471.39M307.53M
Short-term Investments00000
Net Receivables13K62K5.16M00
Inventory00000
Other Current Assets766K1.71M3.49M1.17M1.75M
Total Current Assets584.81M719.1M639.28M485.41M315.19M
Property, Plant & Equipment (Net)14.14M8.01M16M13.79M10.27M
Goodwill00000
Intangible Assets00000
Long-term Investments000860K860K
Tax Assets7.07M18.2M33.89M43.24M0
Other Non-current Assets3.35M12.73M7.21M3.81M482K
Total Non-current Assets24.56M38.94M57.1M61.7M11.61M
Total Assets609.37M758.04M696.38M547.11M326.8M
Account Payables3.69M9.27M25.39M7.77M5.88M
Short-term Debt00002.89M
Tax Payables00000
Deferred Revenue7.66M11.44M08.85M2.66M
Other Current Liabilities405K503K2.13M1.38M29.42M
Total Current Liabilities33.45M50.15M56.89M48.5M40.84M
Long-term Debt00005.49M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)102.93M85.29M67.41M3.45M0
Other Non-current Liabilities553K553K00(5.49M)
Total Non-current Liabilities109.87M85.85M78.13M11.68M5.49M
Total Liabilities143.32M135.99M135.02M60.18M46.33M
Common Stock466K521K537K538K538K
Retained Earnings(716.05M)(833M)(980.03M)(1.1B)(1.35B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity466.04M622.04M561.37M486.93M280.47M
Total Debt12.33M6.47M11.84M10.84M13.86M
Net Debt(566.77M)(703.93M)(607M)(460.55M)(293.67M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.